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1. Introduction 
The recognition that the plasma membrane (PM) is 
the site of reception, modulation and transfer of sig- 
nals that lead to the cell’s responses has aroused much 
recent interest in the possibility that modification of 
membrane phospholipids (PL) is important in frans- 
membrane signalling. Modification of PL requires the 
participation of phospholipases. For example,>he 
removal of fatty acids by deacylating enzymes may 
trigger their replacement with fatty acids differing in 
physical properties, thereby changing membrane 
fluidity. 
The polymorphonuclear leukocyte @‘MN) provides 
an example of a cell thought to undergo PL modifica- 
tion as part of its typical functions, including chemo- 
taxis and phagocytosis [l-3]. The pathways of PL 
synthesis and degradation have been well studied in 
PMN [4]. Phospholipase AZ (PLA2) and lysophos- 
pholipase activities have been identified in human 
and rabbit PMN [5--g]. The PLAZ of PMN is particu- 
late and is predominantly associated with the mem- 
branes of both specific and azurophil granules [ 5,7], 
but may also occur in other membranes including the 
PM [5,7]. 
It has been speculated that in PMN the arachidonic 
acid precursor for prostaglandin synthesis is preferen- 
tially hydrolyzed by PM PLA2 from lecithin that in 
turn is derived from PM phosphatidylethanolamine via 
the methylation pathway [3]. However, evidence per- 
mitting the conclusion that these metabolic events, 
including the action of a PLA2, actually occur in the 
PM, has not been presented. 
We now demonstrate the presence of PLAZ in the 
PM of human PMN, using a cell fractionation proce- 
dure that provides a highly purified PM preparation in 
high yield [9]. Thus, an essential enzyme in the 
metabolism of PL of PMN is present in a strategic 
location in or at the cell surface. This may support 
the contention that functionally important PL altera- 
tions occur in the PM. 
2. Experimental 
Human PMN isolation and fractionation were car- 
ried out as in [9]. Particulate PMN fractions were dis- 
rupted by aspiration through a 25 gauge needle and/or 
by freeze-thaw treatment before measurement of 
PMN activities and protein. These fractions were also 
extracted with 0.16 N H2S04 to solubilize PLA and a 
bactericidal protein as in [ 10,l 11. This was necessary to 
optimize the assay of PLA activity. 
Bacteria: Rough Escherichia coli were cultured in 
a triethanolamine-buffered (pH 7.75-7.9) minimal 
salts medium as in [lo]. Bacterial PL were labeled 
specifically in the 1 - or 2acyl position by growth of 
E. coli in medium containing [ 1 -14C] palmitic acid or 
[ 1 -14C] oleic acid (both 60 Ci/mol (Amersham Searle 
Corp.)) [12]. 
PLA activity of PMN fractions toward [ 14C] fatty- 
acid-labeled E. coli (autoclaved to inactivate bacte- 
rial PLA and to render bacterial PL readily degradable 
by added PLA [5]) was measured during incubation 
at 37°C for 1 h in a mixture also containing 80 mM 
buffer (typically Tris-HCl (PH 7.5)) and 10 mM 
CaCl*. Hydrolysis and its positional specificity were 
determined by thin-layer chromatographic separation 
of lipid-extracted free fatty acids, monoacylphospha- 
tides and diacylphosphatides and counting of the 
labeled lipid species as in [ 81. 
The presence of a granule-associated bactericidal/ 
permeability-increasing protein (BPI) [lo] in the vari- 
298 
Published by ElsevierlNorth-Holland Biomedical Press 
00145793/81/0000-0000/$02.75 0 1981 Federation of European Biochemical Societies 
Volume 136, number 2 FEBS LETTERS December 1981 
ous subcellular fractions was determined by measur- 
ing the bactericidal activity of these fractions towards 
rough E. coli. Essentially alI bactericidal activity of 
crude human PMN fractions toward rough E. coZi is 
attributable to BP1 [IO]. Incubations and measure- 
ments of bacterial viability were carried out as in 
[IO]. The concentration of BP1 in acid extracts was 
also measured immunochemically by the method in 
[ 131, using specific goat anti-human BP1 serum. 
Lysozyme activity in the various subcellular frac- 
tions was measured turbidometrically by the rate of 
lysis of Micrococcus lysodeikticus [ 141. Protein was 
measured by the method in [ 1.51. 
3. Results and discussion 
PM and human PMN can be obtained in high yield 
and purity, using nitrogen cavitation to break the 
cells and differential centrifugation, as in [9]. 
Table 1 shows the distribution and recovery of 
protein, lysozyme, PLA activity, and a potent granule- 
associated bactericidal protein [lo], among PMN 
fractions obtained by this method. This fractionation 
procedure produced the expected protein and lyso- 
zyme distribution, indicating that the PM containing 
preparation (pellet 3) is almost free of granule con- 
tents. This conclusion is further supported by the 
finding that only 1% of granule-associated BP1 is 
found in pellet 3. Thus, BP1 is a useful marker for 
human PMN granules, particularly because this pro- 
tein is tightly associated with the granule membranes 
and is not released during fractionation [ 111. 
The granule fraction also contains most of the 
recovered PLA activity. However, in contrast to the 
distribution of lysozyme and BP1 activities, nearly 
20% of the recovered PLA activity is present in pel- 
let 3 (PM containing fraction). The PLA activity of 
pellet 3 is equally distributed between endoplasmic 
reticulum (ER) and PM vesicles (table 2). ER and PM 
vesicles were separated by dextran density gradient 
centrifugation [9]. The ER, a site of considerable 
PLA activity in other cells [ 161, is the subcellular 
fraction with the highest specific PLA activity in 
PMN. The remaining PLA activity in the purified PM 
fraction nevertheless exceeds what could be accounted 
for by a contamination with ER and/or granules. 
Moreover, the tight association of the PLA activity 
with any PMN-membrane preparation in which it 
occurs renders it unlikely that the phospholipase(s) of 
the PMN is(are) redistributed during fractionation. 
Table 1 
Subcellular distribution of phospholipase activity in human PMN 
Fraction Protein Lysozyme BP1 Phospholipase A 
c(g Recov- Unitsb Recov- UnitsC Recov- Unitsd Recov- 
ery(%)a cry(%) cry(%) cry(%) 
Whole cavitated sample 104.5 f 41 100 180 100 8.4 100 25.8 f 8.2 100 
(4) (2) (2) (7) 
Pellet 1 99 f 19 14 14+ 8 8 1.9 22.6 1.7 + 0.7 7 
(nuclei + intact cells) (5) (5) (2) (7) 
Pellet 2 110 f 9 15.6 168kll 90 6.4 k 1.1 76.2 11.0 k 2.6 43 
(granules) (5) (5) (7) 
Pellet 3 7.9 f 0.7 1.1 6+ 1 3.5 0.1 f 0.1 1.2 2.8 + 0.9 11 
(plasma membrane-rich) (5) (4) (7) 
Supernatant 3 295 f 34 41.8 n.d. <0.4 - <O.l - 
(5) (1) (1) 
a Recovery in each fraction is given as % of activity in whole cavitated sample: Activities are given as arbitrary units/lo’ PMN 
(mean f SEM); (n) = number of independent determinations carried out at least in duplicate; n.d. = not determined 
b Lysozyme, one unit = ti 450 x lO”/min; c BPI, one unit = 90% loss of viability of 5 X lo6 E. coli; d Phospholipase A, one 
unit = 1% hydrolysis of 5 nmol phospholipid/h 
Nitrogen cavitation and differential centrifugation were carried out as in 191. For detailed description of assays for phospholipase A, 
bactericidal (BPI) and lysozymal activities see references in section 2 
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Table 2a 
Subfraction of pellet 3 
Fraction Protein Phospholipase A 
recovery(%) recovery(%) 
Pellet 3 100 100 
Plasma membranes 68.4 f 18.2 59t 9.4 
(6) (5) 
Endoplasmic reticulum 18.7 c 13 66r 13 
(6) (5) 
a See legend of table 1 
The PLA activity of all subcellular fractions shows 
a high degree of positional specificity. Using E. coli, 
autoclaved after labeling with [‘“Cl oleic acid (>95% 
incorporated into the 2-position of E. coli phospho- 
lipids) or with [14C]palmitic acid (X0% incorpo- 
rated into the I-position) [ 121, as substrate for assays 
of PLA activity, revealed that 280% of hydrolysis by 
all PMN fractions is attributable to PLA? activity, 
confirming observations on crude human PMN frac- 
tions [ 5,7]. The pH profiles of PLAZ activity in all 
fractions are superimposable, showing a main seak 
between pH 7-8 and a second minor peak at pH 5.5 
(not shown). At pH 5.5 as well as at pH 7.5 activity 
requires Ca2+ and is abolished by 5 mM EDTA in line 
with our report on crude human PMN fractions [7]. 
Thus, although these studies suggest hat more 
than one PLAZ activity may be present in human 
PMN, differing in pH optimum, we have so far found 
no evidence of heterogeneity related to cellular 
(membrane) distribution. However, functional differ- 
ences in PLA? activity may exist on the basis of cellu- 
lar location rather than catalytic properties of the 
enzyme [5]. 
We have shown that PMN-PLA2 is involved in 
degradation of PL of bacteria ingested and killed by 
the PMN [ 12,I 7,181. Net degradation of PL of several 
Gram-negative bacterial species appears linked to the 
bactericidal action of BP1 [8], which facilitates in 
highly specific manner hydrolysis by PMN-PL& [ 171. 
Since BP1 is only found in association with the 
granules, it is tempting to suggest an anatomical seg 
regation of PLAZ function in this cell: 
(1) 
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Phospholipase(s) AZ associated with the mem- 
branes of both specific and azurophil granules 
[5,7] that participate, after degranulation, in the 
intravacuolar antibacterial assault of the PMN on 
ingested bacteria; 
(2) PLAZ activity in other PMN membranes, presum- 
ably concerned with endogenous PL metabolism. 
Our evidence of PLA2 activity in the plasma mem- 
brane of the PMN should provide further impetus to 
the search for the connection between surface per- 
turbation, activation of PLA?, PL remodeling and 
conversion of released arachidonic acid to biologically 
active derivatives, and the triggering of specific PMN 
functions. 
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